Endologix (ELGX) Upgraded at BidaskClub

Endologix (NASDAQ:ELGX) was upgraded by BidaskClub from a “sell” rating to a “hold” rating in a report issued on Saturday.

A number of other research analysts have also recently weighed in on ELGX. Zacks Investment Research cut shares of Endologix from a “hold” rating to a “sell” rating in a research report on Tuesday, January 30th. Stifel Nicolaus cut their price target on shares of Endologix from $6.00 to $5.50 and set a “hold” rating on the stock in a report on Wednesday, November 8th. Canaccord Genuity restated a “hold” rating and issued a $5.00 price target on shares of Endologix in a report on Wednesday, November 8th. Piper Jaffray Companies restated an “overweight” rating on shares of Endologix in a report on Tuesday, December 12th. Finally, Royal Bank of Canada cut their price target on shares of Endologix from $5.00 to $4.00 and set a “sector perform” rating on the stock in a report on Wednesday, November 8th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $5.41.

Endologix (ELGX) traded up $0.03 during mid-day trading on Friday, reaching $4.13. 503,459 shares of the company’s stock were exchanged, compared to its average volume of 545,685. The company has a debt-to-equity ratio of 2.61, a current ratio of 2.90 and a quick ratio of 2.11. Endologix has a fifty-two week low of $4.00 and a fifty-two week high of $7.66. The company has a market capitalization of $341.33, a PE ratio of -4.44 and a beta of 0.42.

Endologix (NASDAQ:ELGX) last posted its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported ($0.11) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.17) by $0.06. Endologix had a negative net margin of 41.60% and a negative return on equity of 52.18%. The business had revenue of $45.99 million for the quarter, compared to analysts’ expectations of $47.21 million. equities research analysts forecast that Endologix will post -0.61 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of ELGX. Schwab Charles Investment Management Inc. grew its holdings in shares of Endologix by 10.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 321,309 shares of the medical instruments supplier’s stock worth $1,562,000 after purchasing an additional 30,429 shares during the last quarter. Swiss National Bank grew its holdings in shares of Endologix by 14.3% in the second quarter. Swiss National Bank now owns 137,900 shares of the medical instruments supplier’s stock worth $670,000 after purchasing an additional 17,300 shares during the last quarter. Alliancebernstein L.P. grew its holdings in shares of Endologix by 11.5% in the second quarter. Alliancebernstein L.P. now owns 108,757 shares of the medical instruments supplier’s stock worth $529,000 after purchasing an additional 11,200 shares during the last quarter. Teachers Advisors LLC grew its holdings in Endologix by 40.8% during the 2nd quarter. Teachers Advisors LLC now owns 198,912 shares of the medical instruments supplier’s stock worth $967,000 after acquiring an additional 57,675 shares in the last quarter. Finally, TIAA CREF Investment Management LLC grew its holdings in Endologix by 48.5% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 324,193 shares of the medical instruments supplier’s stock worth $1,576,000 after acquiring an additional 105,895 shares in the last quarter.

COPYRIGHT VIOLATION WARNING: This report was reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2018/02/10/endologix-elgx-upgraded-at-bidaskclub.html.

About Endologix

Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

Analyst Recommendations for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply